208 related articles for article (PubMed ID: 36480560)
21. A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study.
Welty FK; Lewis SJ; Friday KE; Cain VA; Anzalone DA
J Womens Health (Larchmt); 2016 Jan; 25(1):50-6. PubMed ID: 26539650
[TBL] [Abstract][Full Text] [Related]
22. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
J Atheroscler Thromb; 2011; 18(11):1018-28. PubMed ID: 21921413
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
Martin PD; Mitchell PD; Schneck DW
Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
[TBL] [Abstract][Full Text] [Related]
25. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
[TBL] [Abstract][Full Text] [Related]
26. Cerivastatin for lowering lipids.
Adams SP; Tiellet N; Alaeiilkhchi N; Wright JM
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012501. PubMed ID: 31981471
[TBL] [Abstract][Full Text] [Related]
27. Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.
Yamamoto A; Arakawa K; Sasaki J; Matsuzawa Y; Takemura K; Tsushima M; Fujinami T; Mabuchi H; Itakura H; Yamada N; Toyota T; Oikawa S;
J Atheroscler Thromb; 2002; 9(1):48-56. PubMed ID: 12238638
[TBL] [Abstract][Full Text] [Related]
28. The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-Lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-Density Lipoprotein.
Kim TE; Shin D; Gu N; Jung BH; Kim J; Cho YM; Yu KS; Cho JY
Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):195-201. PubMed ID: 28627804
[TBL] [Abstract][Full Text] [Related]
29. Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients.
Ghazeeri G; Abbas HA; Skaff B; Harajly S; Awwad J
J Endocrinol Invest; 2015 Jun; 38(6):643-51. PubMed ID: 25722221
[TBL] [Abstract][Full Text] [Related]
30. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of rosuvastatin in Taiwanese patients.
Chiang CE; Huang SS; Sung SH
J Chin Med Assoc; 2008 Mar; 71(3):113-8. PubMed ID: 18364261
[TBL] [Abstract][Full Text] [Related]
32. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
Mora S; Glynn RJ; Ridker PM
Circulation; 2013 Sep; 128(11):1189-97. PubMed ID: 24002795
[TBL] [Abstract][Full Text] [Related]
33. Periodic rosuvastatin or atorvastatin dosing arrays (PRADA): patient-centered practice.
Christou T; Omar HR; Dimitrov R
Drugs R D; 2014 Dec; 14(4):221-5. PubMed ID: 25160776
[TBL] [Abstract][Full Text] [Related]
34. HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
Liang K; Kim CH; Vaziri ND
Am J Physiol Renal Physiol; 2005 Mar; 288(3):F539-44. PubMed ID: 15507547
[TBL] [Abstract][Full Text] [Related]
35. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosenson RS
Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
[TBL] [Abstract][Full Text] [Related]
36. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
[TBL] [Abstract][Full Text] [Related]
37. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
38. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
[TBL] [Abstract][Full Text] [Related]
39. Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India.
Roy D; Mahapatra T; Manna K; Kar A; Rana MS; Roy A; Bose PK; Banerjee B; Paul S; Chakraborty S
PLoS One; 2020; 15(5):e0233230. PubMed ID: 32428019
[TBL] [Abstract][Full Text] [Related]
40. Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin.
Cai G; Zhang B; Shi G; Weng W; Yang L; Xue S
Lipids Health Dis; 2016 Sep; 15(1):148. PubMed ID: 27600285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
